Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The study aims to test if combination of sorafenib and omacetaxine mepesuccinate (OM, also
known as homoharringtonine) results in durable composite complete remission (CRc) in patients
with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying
FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).